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zone is indicated in combination with insulin. They
are highly metabolized by the liver and should not
be used in patients with liver enzymes greater than
2.5 times the upper limit of normal. Routine liver
monitoring is recommended at baseline, every 2
months for the first year, and then periodically there-
after.1 Patients with New York Heart Association class
III or IV heart failure should not use thiazolidine-
diones. In addition, thiazolidinediones cost consid-
erably more than sulfonylureas and metformin.14
Therefore, thiazolidinediones are not generally con-
sidered for first-line therapy.15 These agents may be
most beneficial in patients with insulin resistance
and patients with renal dysfunction.1
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How beneficial are thiazolidinediones 
for diabetes mellitus?
EVIDENCE-BASED ANSWER The thiazolidine-
diones pioglitazone (Actos) and rosiglitazone
(Avandia) are effective at lowering fasting plasma glu-
cose (FPG) and glycosylated hemoglobin (Hb A1c) in
patients with type 2 diabetes when used either as
monotherapy or in combination with sulfonylureas,
metformin, or insulin. The glucose-lowering
effects appear comparable with those of sul-
fonylureas and metformin alone. Currently,
there are no randomized trials directly compar-
ing patient-oriented outcomes of the thiazo-
lidinediones with those of sulfonylureas and
metformin. Grade of recommendation: B (on
the basis of extrapolations from randomized tri-
als and low quality randomized trials). 
EVIDENCE SUMMARY Proper nutrition and
exercise remain the cornerstones of diabetes
therapy; medication management, however, is
often necessary.1 Both pioglitazone and rosigli-
tazone have similar glucose-lowering effects.
See the tables in the online version of this
Clinical Inquiry at www.fpin.org for a summary
of monotherapy and combination clinical trials. 
Pioglitazone has consistently been shown to
decrease triglycerides and increase high-densi-
ty lipoprotein and rosiglitazone increases total
cholesterol, HDL, and low-density lipoprotein.
The clinical significance of these effects has
not been established. Both medications are
generally well tolerated but have the potential
to cause edema and mildly decrease hemoglobin and
hematocrit.2-9
To date, there have been reports of pulmonary
edema and hepatotoxicity associated with the use of
rosiglitazone. In all cases, rosiglitazone was found to
be a possible, not a definite, cause.10-12
RECOMMENDATIONS FROM OTHERS The
American Diabetes Association and the American
Association of Clinical Endocrinologists do not rec-
ommend one class of antidiabetic medication over
another.1,13 Both of the thiazolidinediones are indicat-
ed for monotherapy and in combination with a sul-
fonylurea and metformin. However, only pioglita-
Effects of rosiglitazone and pioglitazone, by dosage
Drug and Control Adjunct Change in Hb A1c Change in FPG 
dosage medication vs comparison vs comparison 
(%) (mg/dL)
Rosiglitazone
4 mg bid2 placebo none -1.5* -73*
2 mg bid3 glyburide none +0.4 +5
4 mg bid +0.2† -11
8 mg bid4 placebo metformin -1.3* -54.3*
2 mg bid5 placebo sulfonylurea -1.1* -43.6*
4 mg bid6 placebo insulin -1.3‡ -55.8‡
Pioglitazone
45 mg qd7 placebo none -1.6* -65.3*
30 mg qd8 placebo sulfonylurea -1.3* -57.9*
30 mg qd9 placebo metformin -0.83* -37.7*
Hb A1c denotes glycosylated hemoglobin; FPG, fasting plasma glucose; bid, twice a day; qd, every day.
*P < .05 versus control.
†P= not significant.
‡P= < .006 versus placebo plus insulin.
Find further details online at www.fpin.org.
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